These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34109794)
1. Prodrug Delivery Using Dual-Targeting Nanoparticles To Treat Breast Cancer Brain Metastases. Ju X; Chen H; Miao T; Ni J; Han L Mol Pharm; 2021 Jul; 18(7):2694-2702. PubMed ID: 34109794 [TBL] [Abstract][Full Text] [Related]
2. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. Guo Q; Zhu Q; Miao T; Tao J; Ju X; Sun Z; Li H; Xu G; Chen H; Han L J Control Release; 2019 Jun; 303():117-129. PubMed ID: 31026546 [TBL] [Abstract][Full Text] [Related]
3. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy. Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081 [TBL] [Abstract][Full Text] [Related]
4. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer. Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581 [TBL] [Abstract][Full Text] [Related]
5. Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy. Li M; Shi K; Tang X; Wei J; Cun X; Long Y; Zhang Z; He Q Nanomedicine; 2018 Aug; 14(6):1833-1843. PubMed ID: 29800759 [TBL] [Abstract][Full Text] [Related]
6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
7. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood-tumor barrier for boosted brain tumor therapy. Mu R; Sun H; Zeng Y; Tong Y; Tang P; Zhao M; Lv Z; Yu J; Chen Y; Lan Q; Zhen X; Han L J Control Release; 2024 May; 369():458-474. PubMed ID: 38575077 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328 [TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin. Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431 [TBL] [Abstract][Full Text] [Related]
11. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy. Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147 [TBL] [Abstract][Full Text] [Related]
12. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles. Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221 [TBL] [Abstract][Full Text] [Related]
13. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677 [TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid wreathed, trio-stimuli receptive and on-demand triggerable nanoconstruct for anchored combinatorial cancer therapy. Poudel K; Banstola A; Tran TH; Thapa RK; Gautam M; Ou W; Pham LM; Maharjan S; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO Carbohydr Polym; 2020 Dec; 249():116815. PubMed ID: 32933663 [TBL] [Abstract][Full Text] [Related]
15. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765 [TBL] [Abstract][Full Text] [Related]
17. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier. Wang X; Mao W; Wang Z; Li X; Xiong Y; Lu H; Wang X; Yin H; Cao X; Xin H Int J Nanomedicine; 2020; 15():5491-5501. PubMed ID: 32848385 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Cui T; Zhang S; Sun H Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466 [TBL] [Abstract][Full Text] [Related]
19. Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer. Xu C; Xu J; Zheng Y; Fang Q; Lv X; Wang X; Tang R J Mater Chem B; 2020 Apr; 8(13):2726-2737. PubMed ID: 32154530 [TBL] [Abstract][Full Text] [Related]
20. Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy. Wang Y; Wang J; Yang L; Wei W; Sun B; Na K; Song Y; Zhang H; He Z; Sun J; Wang Y Nanomedicine; 2019 Oct; 21():102066. PubMed ID: 31351237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]